From Health Plan Week - New moves by PBMs Express Scripts Holding Co. and CVS/caremark to stake out exclusionary formulary arrangements for managing the use of high-priced hepatitis C specialty drugs have health insurers measuring the impact of the deals, with an eye on how the competition may lower the cost for these treatments and others in the same class. One major carrier, Anthem Inc., on Jan. 8 joined the fray when it declared that favorable pricing and clinical differences led it to choose Gilead Sciences, Inc.’s Harvoni hep C drug as the primary treatment for its members. Read more
From The AIS Report on Blue Cross and Blue Shield Plans - Despite strong evidence that some women with early stage breast cancer can achieve the same results with a shorter course of treatment, many radiation oncologists haven’t changed their treatment regimens, according to the results of a study published Dec. 17 in the Journal of the American Medical Association (JAMA). The study — conducted by the University of Pennsylvania, Anthem, Inc. and its outcomes research subsidiary, HealthCore — is the first… Read more
From The AIS Report on Blue Cross and Blue Shield Plans - Blues plan operator Anthem, Inc. is teaming up with pharma giants Boehringer Ingelheim (BI) and Eli Lilly and Co. to identify gaps in care and explore real-world effects of prescription drugs through two separate five-year research agreements. Read more
Check out all of the benefits, sample issues & more!